Best Practices in Engagement of All Health Care Providers in the Management of Drug-resistant Tuberculosis PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Best Practices in Engagement of All Health Care Providers in the Management of Drug-resistant Tuberculosis PDF full book. Access full book title Best Practices in Engagement of All Health Care Providers in the Management of Drug-resistant Tuberculosis by WHO Global TB Programme. Download full books in PDF and EPUB format.
Author: WHO Global TB Programme
Publisher:
ISBN: 9789241509541
Category : Drug resistance
Languages : en
Pages : 20
Get Book Here
Book Description
"This publication documents best practices in engagement of health-care providers in the management of drug-resistant tuberculosis (DR-TB). The aim is to share experiences and approaches that are being implemented in countries and by various health-care providers and partners. Some of the case studies in this document are also presented in the WHO's Framework for engagement of all health-care providers in the management of drug-resistant tuberculosis. In the current document, case studies are presented by approach, for easier reference by readers who are interested in examples and experiences around the globe in implementation of public-private mix for DR-TB (PPM DR-TB). The WHO/Global TB Programme (GTB) team continues to document best practices for sharing in the public domain via the WHO/GTB website. National TB programmes and partners are encouraged to share their case studies with others via the website."--Page 3.
Author: WHO Global TB Programme
Publisher:
ISBN: 9789241509541
Category : Drug resistance
Languages : en
Pages : 20
Get Book Here
Book Description
"This publication documents best practices in engagement of health-care providers in the management of drug-resistant tuberculosis (DR-TB). The aim is to share experiences and approaches that are being implemented in countries and by various health-care providers and partners. Some of the case studies in this document are also presented in the WHO's Framework for engagement of all health-care providers in the management of drug-resistant tuberculosis. In the current document, case studies are presented by approach, for easier reference by readers who are interested in examples and experiences around the globe in implementation of public-private mix for DR-TB (PPM DR-TB). The WHO/Global TB Programme (GTB) team continues to document best practices for sharing in the public domain via the WHO/GTB website. National TB programmes and partners are encouraged to share their case studies with others via the website."--Page 3.
Author:
Publisher: World Health Organization
ISBN: 9240027033
Category : Medical
Languages : en
Pages : 83
Get Book Here
Book Description
The 2020 update of the landscape analysis on private sector engagement aims to facilitate improved engagement of private providers, thereby contributing to universal access to quality and affordable TB care and the end of the TB epidemic. It focuses on the role of private for-profit providers and on specific challenges and experiences in engaging them for TB prevention and care.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241547588
Category : Business & Economics
Languages : en
Pages : 271
Get Book Here
Book Description
The emergence of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, is a serious threat to global public health and jeopardizes efforts to effectively control the disease. This publication offers updated recommendations for the diagnosis and management of drug-resistant tuberculosis in a variety of geographical, economic and social settings, and the recording of data that enables the monitoring and evaluation of programs.--Publisher's description.
Author: World Health Organization
Publisher:
ISBN: 9789241504508
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
"Tuberculosis (TB) affected an estimated 8.7 million people and caused 1.4 million deaths globally in 2011, including 0.5 million women and at least 64 000 children. About 13% of TB occurs among people living with HIV, and TB causes almost a quarter of AIDS deaths. There is evidence of links between TB and noncommunicable diseases such as diabetes mellitus and with determinants of ill-health like tobacco and drug use, alcoholism and malnutrition. TB mostly affects the productive segment of society in their prime. One third of people estimated to have TB are either not reached for diagnosis and treatment by the current health systems or are not being reported. Even in patients who are identified, TB is often diagnosed and treated late. In order to reach the unreached and to find TB patients early in the course of their illness, a wider range of stakeholders already involved in community-based activities needs to be engaged. These include the nongovernmental organizations (NGOs) and other civil society organizations (CSOs) that are active in community-based development, particularly in primary health care, HIV infection and maternal and child health, but have not yet included TB in their priorities and activities. NGOs and other CSOs are non-profit organizations that operate independently from the state and from the private for-profit sector. They include a broad spectrum of entities such as international, national and local NGOs, community-based organizations (CBOs), faith-based organizations (FBOs), patient-based organizations and professional associations. CBOs are membership-based non-profit organizations that are usually self-organized in specific local areas (such as a village) to increase solidarity and mutual support to address specific issues. For example, these include HIV support groups, women's groups, parent-teacher associations and micro-credit village associations. CBO membership is comprised entirely of community members themselves, so these organizations can be considered to represent the community most directly. NGOs and other CSOs engage in activities that range from community mobilization, service delivery, and technical assistance to research and advocacy. The strengths of NGOs and other CSOs active in health care and other development interventions at the community level include their reach and spread and their ability to engage marginalized or remote groups. These organizations have a comparative advantage because of their understanding of the local context. Greater collaboration between NGOs and other CSOs and local and national governments could greatly enhance development outcomes. A more decentralized approach that formally recognizes the critical role of NGOs and other CSOs as partners addressing gaps through support to community-based actions will expand TB prevention, diagnosis, treatment and care activities. Community-based TB activities cover a wide range of activities contributing to prevention, diagnosis, improved treatment adherence and care that positively influence the outcomes of drug-sensitive, drug resistant and HIV-associated TB. The activities also include community mobilization to promote effective communication and participation among community members to generate demand for TB prevention, diagnosis, treatment and care services. While diagnostic tests for TB continue to be performed in clinical settings, for lack of simpler diagnostic methods, community-based TB activities are conducted outside the premises of formal health facilities (e.g. hospitals, health centres and clinics) in community-based structures (e.g. schools, places of worship, congregate settings) and homesteads. Such community-based TB activities could and should be integrated with other community-based activities supporting primary health care services, including those for HIV infection, maternal and child health and noncommunicable diseases to improve synergy and impact. Community-based TB activities utilize community structures and mechanisms through which community members, CBOs and groups interact, coordinate and deliver their responses to the challenges and needs affecting their communities."--Page 1.
Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Get Book Here
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240089721
Category : Medical
Languages : en
Pages : 7
Get Book Here
Book Description
In this Rapid Communication, the World Health Organization (WHO) is announcing a number of updates to its forthcoming 2nd edition of the guidance on tuberculosis preventive treatment (TPT). This will help national tuberculosis (TB) programmes, public and private healthcare providers, funders and other stakeholders to prepare for the changes that will be introduced when the updated guidelines and accompanying operational handbook on TPT are released later this year. Effective TPT in people at highest risk of progression safely reduces the likelihood of developing TB disease. This includes individuals exposed to multidrug- or rifampicin-resistant TB (MDR/RR-TB). The updated guidance will avail of the latest evidence and best available practices on TPT regimens for individuals of all ages in contact with TB patients and dosing schedules. It will also incorporate current recommendations on screening strategies to rule out TB disease ahead of starting TPT, and the use of tests of TB infection.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240007040
Category : Medical
Languages : en
Pages : 120
Get Book Here
Book Description
BACKGROUND: Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). WHO estimates that about half a million cases of multi-drug or rifampicin resistant (MDR/RR-TB) are estimated to occur each year. However, only one third were estimated to have accessed effective treatment and of those, just over half had a successful treatment outcome. Therefore, there is a pressing need for evidence-based policy recommendations on the treatment and care of patients with DR-TB, based on the most recent and comprehensive evidence available. In this regard, the WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment fulfills the mandate of WHO to inform health care professionals in Member States on how to improve treatment and care for patients with DR-TB. The 2020 recommendations on drug resistant TB treatment are contained in the second module to be released under the rubric of WHO Consolidated Guidelines on Tuberculosis (Module 4: Treatment). The WHO Consolidated Guidelines on Tuberculosis will group all TB recommendations in one document and will be complemented by matching modules of a consolidated operational handbook. The operational handbook will provide practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact. OVERVIEW: Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309130441
Category : Medical
Languages : en
Pages : 252
Get Book Here
Book Description
Tuberculosis is one of the leading causes of death in the world today, with 4,500 people dying from the disease every day. Many cases of TB can be cured by available antibiotics, but some TB is resistant to multiple drugs-a major and growing threat worldwide. The Institute of Medicine's Forum on Drug Discovery, Development, and Translation hosted a workshop on November 5, 2008, to address the mounting concern of drug-resistant TB. The session brought together a wide range of international experts to discuss what is known and not known about this growing threat, and to explore possible solutions.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240063129
Category : Medical
Languages : en
Pages : 134
Get Book Here
Book Description
Author:
Publisher: World Health Organization
ISBN: 9240006990
Category : Medical
Languages : en
Pages : 88
Get Book Here
Book Description
With the availability of new emerging evidence on the treatment of drug resistant TB (DR-TB), the WHO has recently updated the DR-TB treatment guidelines by convening a guideline development group meeting in 2019 and then by releasing the WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment in June 2020. These guidelines include a comprehensive set of WHO recommendations, grouping all new and existing recommendations on the treatment and care of DR-TB in one document. The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment provides practical guidance on how to put in place the recommendations at the scale needed to achieve national and global impact. The strategies described in the operational handbook are based on the latest WHO recommendations which were formulated by Guideline Development Groups using the GRADE approach. In many cases however, the recommendations in their current form lacked sufficient clinical and programmatic detail, which is important for implementation. This operational handbook complements the guidelines with practical advice based on best practices and knowledge from the fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance and clinical and programmatic management.
